Loading clinical trials...

China 3T MRI Study | Clinical Trials | Clareo Health

COMPLETEDNA

China 3T MRI Study

China CIED 3.0T MRI Performance Study

NCT06038123•Medtronic Cardiac Rhythm and Heart Failure

Summary

The purpose of the China CIED 3.0T MRI Performance Study is to confirm safety of SureScan CIED in the clinical 3.0T MRI environment when subjects receive MRI scans. All subjects will have required follow-up visits at baseline, MRI visit, 1-month post-MRI. The MRI scans will occur at the MRI visit. The MRI scan region will be determined by investigator according to the subject's clinical condition.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Subjects who were implanted an SureScan system CIED over 6 weeks at the time of signing ICF.
•Subjects who are able and willing to undergo elective MRI scanning without sedation.
•Subjects who were implanted an SureScan system CIED in the pectoral region.
•Subjects who are geographically stable and available for follow-up at the study site for the length of the study.
•Subjects who are at least 18 years of age (or older, if required by local law).

Exclusion Criteria

•Subjects who require a legally authorized representative to obtain informed consent.
•Subjects with abandoned or capped leads.
•Subjects who require an indicated MRI scan, other than those specifically described in the China CIED 3.0T MRI performance study, before the 1-month post-MRI follow-up.
•Subjects with a non-MRI compatible device (such as neurostimulators) or material implant (e.g., non-MRI compatible sternal wires, neurostimulators, biostimulators, metals or alloys).
•Subjects with medical conditions that preclude the testing required by the CIP or limit study participation.
•Subjects who are enrolled or intend to participate in another clinical trial (of an investigational drug or device, new indication for an approved drug or device, or requirement of additional testing beyond standard clinical practice) during the SureScan study. Co-enrollment in concurrent trials is only allowed when documented pre-approval is obtained from the Medtronic study manager.
•Female patient who is pregnant, or of childbearing potential and not on a reliable form of birth control. Women of childbearing potential are required to have a negative pregnancy test within seven (7) days prior to device implant.

Locations (5)

Nanfang Hospital Southern Medical University

Guangzhou, Guangdong, China

Affiliated Hospital of Zunyi Medical University

Zunyi, Guizhou, China

Shanghai Tongren Hospital

Shanghai, Shanghai Municipality, China

Shanxi Cardiovascular Hospital

Taiyuan, Shanxi, China

The First Affiliated Hospital of Xinjiang Medical University

Ürümqi, Xinjiang, China

Key Dates

Start Date

November 28, 2023

Primary Completion Date

October 17, 2024

Completion Date

October 28, 2024

Last Updated

January 14, 2026

Enrollment

ACTUAL participants

Conditions

BradycardiaTachycardiaHeart Failure

Interventions

China market released 3.0T Magnetic resonance (MR) conditional CIED systems

DEVICE

ReDS-guided Decongestion Strategy in Patients Hospitalized for Heart Failure

NCT07484009

Acute Heart Failure (AHF)Heart Failure (for Example, Fluid Overload)+1 more

View study

RECRUITING

ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies

NCT07191730

CardiotoxicityHeart Failure+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 14, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

China 3T MRI Study

Inclusion Criteria

Exclusion Criteria

ReDS-guided Decongestion Strategy in Patients Hospitalized for Heart Failure

ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies

Hemodynamic Monitoring to Prevent Adverse Events foLlowing cardiOgenic Shock Trial

Proof-of-concept of a Behavioral Intervention to Improve the Cardiovascular Health of People Living With HIV

Autologous Induced Pluripotent Stem Cells of Cardiac Lineage for Congenital Heart Disease

Respiratory Virus Infections in Acute Heart Failure